RecruitingNot ApplicableNCT05243056

A Quality of Life Intervention for Young African American Breast Cancer Survivors in Treatment

Piloting Y-AMBIENT: A Quality of Life Intervention for Young African American Breast Cancer Survivors in Treatment

Sponsor

University of Alabama at Birmingham

Enrollment

40 participants

Start Date

Jun 1, 2022

Study Type

INTERVENTIONAL

Conditions

Summary

This clinical trial studies the use of a quality of life intervention called Y-AMBIENT to help young African American with stage I-III breast cancer manage daily life. Y-AMBIENT is a four-month, telephone-based intervention that includes three themed education sessions with three follow-up sessions, written materials, and videos. The Y-AMBIENT intervention may improve quality of life and other health-related outcomes in young African American breast cancer survivors.

Eligibility

Sex: FEMALEMin Age: 18 YearsMax Age: 44 Years

Plain Language Summary

Simplified for easier understanding

This study tests a supportive care program designed to improve quality of life for young African American women with breast cancer who are currently undergoing treatment. The program combines education, emotional support, and wellness tools delivered through phone and internet. **You may be eligible if...** - You are a biologically born woman who self-identifies as African American - You are between 18 and 44 years old - You have been diagnosed with stage I, II, or III breast cancer - You are currently receiving chemotherapy and/or radiation - You can speak English and have phone and internet access **You may NOT be eligible if...** - You are already enrolled in a formal survivorship navigation program Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERBest Practice

Receive enhanced usual care

OTHEREducational Intervention

Receive Y-AMBIENT

OTHERQuality-of-Life Assessment

Ancillary studies

OTHERQuestionnaire Administration

Ancillary studies

Locations(1)

Ohio State University Comprehensive Cancer Center

Columbus, Ohio, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05243056

Related Trials

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

NCT06058377533 locations

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

NCT05564377479 locations

High Cannabidiol Plant Extract (BRC-001) to Improve Aromatase Inhibitor-Induced Arthralgia in Women With Breast Cancer

NCT065383891 location

Testing Laser Therapy for Treatment of Vaginal Dryness in Survivors of Breast Cancer, The Revitalize Trial

NCT053791531 location

Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer

NCT064340641 location